{"product_id":"questdiagnostics-five-forces-analysis","title":"Quest Diagnostics Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eA Must-Have Tool for Decision-Makers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eQuest Diagnostics faces moderate buyer power and high competitive rivalry amid consolidation and pricing pressure, while supplier power and threat of substitutes remain manageable due to scale and specialized services; regulatory and technological shifts add entry barriers and shape margins. This brief snapshot only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore Quest Diagnostics’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration of High-Tech Equipment Vendors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe market for advanced diagnostic platforms and specialized reagents is concentrated among Roche, Danaher, and Thermo Fisher, which together held roughly 60–70% of the clinical diagnostics and reagents market in 2024. Quest Diagnostics depends on these vendors for PCR, NGS, and immunoassay platforms, so supplier concentration gives them pricing power and limited discounting. Switching vendors would likely require capital outlays of tens to hundreds of millions and months of staff retraining, raising effective switching costs. In 2024 Quest reported 6%–8% capital expenditure growth tied to lab automation upgrades.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Pathologist and Technician Labor\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe limited supply of board-certified pathologists and skilled lab technicians forces Quest Diagnostics to compete tightly for talent, giving workers and unions strong bargaining power over pay and schedules.\u003c\/p\u003e\n\u003cp\u003eBy end-2025 healthcare labor shortages raised median clinical lab technologist wages about 8–12% year-over-year, and Quest reported rising labor costs that pressured 2025 operating margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRising Costs of Logistics and Cold Chain Supply\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMaintaining Quest Diagnostics’ 2,200+ patient service centers and nationwide courier network depends heavily on refrigerated transport and fuel; in 2024 US diesel averaged $4.05\/gal, raising specimen logistics costs by an estimated 6–9% of transport spend. Because sample integrity is critical for diagnostic accuracy, Quest has little room to switch to lower‑cost carriers, giving specialized cold‑chain providers measurable bargaining power over prices and service terms.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Genomic and Proteomic Technologies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAs diagnostics shift to personalized medicine, Quest Diagnostics must license proprietary genomic and proteomic methods from biotech firms that hold patents on key biomarkers and sequencing techniques, driving up costs for high-margin specialized tests.\u003c\/p\u003e\n\u003cp\u003eThese suppliers exert exceptionally high bargaining power in niche areas—no legal or technical substitutes exist—so Quest faces pricing pressure and margin risk; in 2024, \u0026gt;30% of molecular test price increases were tied to patented reagents and IP licensing fees.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh supplier power: patented biomarkers, no substitutes\u003c\/li\u003e\n\u003cli\u003eImpact: higher COGS and reduced margins on specialty tests\u003c\/li\u003e\n\u003cli\u003e2024 data point: \u0026gt;30% of molecular test price rises linked to IP costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependency on IT and Cloud Infrastructure Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eQuest’s shift to AI-driven diagnostics ties it closely to major cloud providers such as AWS and Microsoft Azure, who in 2025 collectively control over 60% of global cloud IaaS market share; they supply the compute and encrypted storage needed for genomic datasets and PHI.\u003c\/p\u003e\n\u003cp\u003eHigh regulatory and cybersecurity stakes (HIPAA, 2023 OCR fines still guiding 2025 practices) create switching costs — migrating petabytes of compressed genomic data and revalidating models can cost tens of millions and months of downtime, weakening Quest’s leverage in SLAs.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003eCloud market \u0026gt;60%: AWS + Azure (2025)\u003c\/li\u003e\n\u003cli\u003eGenomic datasets: petabytes, costly to migrate\u003c\/li\u003e\n\u003cli\u003eSwitching costs: ~$10–50M, months of revalidation\u003c\/li\u003e\n\u003cli\u003eLimited bargaining power on SLAs, high compliance risk\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh supplier power: concentrated platforms, patent price hikes, cloud \u0026amp; labor squeeze\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSupplier power is high: concentrated suppliers (Roche\/Danaher\/Thermo ~60–70% 2024), patented reagents driving \u0026gt;30% molecular test price rises (2024), cloud providers (AWS+Azure \u0026gt;60% IaaS 2025) and scarce lab talent (wages +8–12% YoY 2025) raise switching costs, COGS, and margin pressure.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003e2024–25 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlatform concentration\u003c\/td\u003e\n\u003ctd\u003e60–70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIP-linked price rise\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCloud share\u003c\/td\u003e\n\u003ctd\u003eAWS+Azure \u0026gt;60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLab wages YoY\u003c\/td\u003e\n\u003ctd\u003e+8–12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored Porter's Five Forces analysis for Quest Diagnostics that uncovers competitive intensity, buyer and supplier power, substitution risks, and entry barriers to assess pricing pressure and long-term profitability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-sheet Porter's Five Forces for Quest Diagnostics—quickly spot competitive threats, supplier and buyer leverage, and regulatory risks to inform diagnostics strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsolidation of Managed Care Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpthe health insurance market is highly concentrated: unitedhealth group and elevance together covered about million commercial lives in giving a few payers outsized leverage over providers.\u003e\n\u003cpthey use scale to demand steep discounts and preferred-provider status from quest diagnostics pressuring average revenue per test network placement.\u003e\n\u003cpongoing consolidation through and vertical integration payers bargaining power enabling tougher reimbursement rates compressing quest lab margins.\u003e\n\u003c\/pongoing\u003e\u003c\/pthey\u003e\u003c\/pthe\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIncreased Leverage of Integrated Health Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLarge hospital networks and integrated delivery systems now control ~40% of U.S. hospital beds after 2015–2023 consolidation, creating regional buyers that can internalize routine lab work or demand bulk pricing from Quest Diagnostics.\u003c\/p\u003e\n\u003cp\u003eMany systems perform routine assays in-house and use Quest mainly for high-complexity send-out testing, cutting Quest’s margin mix and pressuring prices.\u003c\/p\u003e\n\u003cp\u003eTo retain contracts, Quest offers discounted rates, population-health analytics, and EHR integrations; in 2024 Quest reported about 18% of revenue tied to institutional clients, underscoring the leverage these systems wield.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernmental Influence through Medicare and Medicaid\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe Centers for Medicare and Medicaid Services (CMS) sets reimbursement via the Clinical Laboratory Fee Schedule, effectively fixing prices across the diagnostics market and constraining Quest Diagnostics’ price setting. The 2014 PAMA (Protecting Access to Medicare Act) and subsequent rate updates cut some routine test reimbursements by ~10–25%, lowering Medicare lab payments by roughly $390 million industry-wide in early years. Quest cannot negotiate CMS rates, so government buying exerts top-down bargaining power that directly pressures margins and revenue growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumerization of Healthcare and Patient Choice\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePatients now act like informed consumers—51% of US insured adults had high-deductible plans in 2024, pushing choices toward lower out-of-pocket costs and convenient care, so Quest must compete on price transparency and patient experience.\u003c\/p\u003e\n\u003cp\u003eBy end-2025, 68% of patients expect digital results and same-day scheduling; that demand elevates individual patients as stronger stakeholders in the diagnostic value chain, shifting bargaining power away from labs.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e51% US insured adults in high-deductible plans (2024)\u003c\/li\u003e\n\u003cli\u003e68% expect digital results and seamless scheduling (2025)\u003c\/li\u003e\n\u003cli\u003eQuest faces pressure on price transparency and patient experience\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Contracting by Large Self-Insured Employers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMajor corporations increasingly bypass insurers to contract directly with diagnostic providers for employee screening; by 2024 about 20% of Fortune 500 firms used direct contracting for health services, offering Quest high-volume prospects.\u003c\/p\u003e\n\u003cp\u003eThese self-insured buyers demand customized analytics and price cuts—contracts often require ≥15% cost savings and outcome-based KPIs tied to utilization and disease detection rates.\u003c\/p\u003e\n\u003cp\u003eQuest must demonstrate clear ROI—showing per-employee savings (example: $120–$300 annually) and measurable clinical impact—to win and keep large accounts in this competitive market.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~20% Fortune 500 use direct contracting (2024)\u003c\/li\u003e\n\u003cli\u003eContracts often require ≥15% cost cuts\u003c\/li\u003e\n\u003cli\u003eExpected per-employee savings $120–$300\/yr\u003c\/li\u003e\n\u003cli\u003eDemand for customized reporting and ROI metrics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuyer power crushes Quest margins—payers, hospitals, and patients force discounts \u0026amp; integrations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cplarge payers elevance and cms exert strong pricing power over quest forcing discounts fixed reimbursements that compressed lab margins by low-double digits after pama cuts hospital systems controlling of beds fortune direct-contracting add regional corporate leverage. patients high-deductible digital expectations want same-day results further shift bargaining toward buyers pushing to offer analytics integrations.\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBuyer\u003c\/th\u003e\n\u003cth\u003e2024–25 stat\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial lives (top payers)\u003c\/td\u003e\n\u003ctd\u003e~70M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospital bed share\u003c\/td\u003e\n\u003ctd\u003e~40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHigh-deductible insured\u003c\/td\u003e\n\u003ctd\u003e51%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients expecting digital\u003c\/td\u003e\n\u003ctd\u003e68%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFortune 500 direct-contract\u003c\/td\u003e\n\u003ctd\u003e~20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/plarge\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eQuest Diagnostics Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Quest Diagnostics Porter’s Five Forces analysis you'll receive immediately after purchase—no surprises, no placeholders.\u003c\/p\u003e\n\u003cp\u003eThe document displayed here is the same professionally written, fully formatted file you’ll be able to download and use the moment you buy.\u003c\/p\u003e\n\u003cp\u003eNo mockups or samples: what you see is the complete, ready-to-use deliverable available instantly after payment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56746708369785,"sku":"questdiagnostics-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/questdiagnostics-five-forces-analysis.png?v=1772191135","url":"https:\/\/matrixbcg.com\/products\/questdiagnostics-five-forces-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}